💊 Pharmaceuticals — Top Stocks by Market Cap
1,859 companies · updated every 5–20 min
| # | Name | Price | 24h % | 7d % | Market Cap | Volume (24h) | Last 7 Days |
|---|---|---|---|---|---|---|---|
| 101 | $23.06 | -0.77% | +3.93% | $11.52B €10.31B | 3.45M shrs $79.64M | ||
| 102 | HK$7.87 | -2.18% | +1.75% | HK$89.7B $11.48B · €10.28B | 76.21M shrs HK$599.37M | ||
| 103 | $72.66 | -0.07% | +26.20% | $11.41B €10.22B | 2.57M shrs $186.43M | ||
| 104 | $58.51 | +1.77% | +2.34% | $11.33B €10.14B | 2.27M shrs $133.02M | ||
| 105 | €229.80 | +0.97% | +3.81% | €10.23B $11.15B | 19.37K shrs €4.45M | ||
| 106 | ₹2011.00 | +1.06% | +1.68% | ₹919.61B $11.04B · €9.88B | 759.4K shrs ₹1.53B | ||
| 107 | ₹2009.00 | +0.55% | — | ₹918.05B $11.02B · €9.86B | 20K shrs ₹40.17M | ||
| 108 | HK$4.82 | -0.62% | -0.90% | HK$85.77B $10.98B · €9.83B | 49.31M shrs HK$237.67M | ||
| 109 | ¥25.60 | +0.63% | +0.77% | ¥78.68B $10.86B · €9.72B | 21.74M shrs ¥556.66M | ||
| 110 | $126.63 | +3.29% | +16.23% | $10.81B €9.68B | 1.59M shrs $201.47M | ||
| 111 | ¥128.59 | +0.95% | +1.29% | ¥77.58B $10.71B · €9.58B | 3.74M shrs ¥480.66M | ||
| 112 | ₩211500.00 | -3.86% | -5.38% | ₩14.7T $10.59B · €9.48B | 331.5K shrs ₩70.11B | ||
| 113 | ¥41.37 | +3.42% | +26.46% | ¥76.01B $10.49B · €9.39B | 53.28M shrs ¥2.2B | ||
| 114 | HK$35.02 | -7.11% | +10.78% | HK$79.86B $10.22B · €9.15B | 68.46M shrs HK$2.4B | ||
| 115 | $430.36 | -0.31% | +0.19% | $9.94B €8.90B | 251.45K shrs $108.21M | ||
| 116 | $332.29 | +2.38% | +9.22% | $9.84B €8.80B | 330.02K shrs $109.66M | ||
| 117 |  Vaxcyte, Inc. PCVX🇺🇸USD | $62.03 | -0.93% | +7.93% | $9.76B €8.74B | 1.71M shrs $106.34M | |
| 118 | $34.33 | -5.01% | +6.53% | $9.7B €8.69B | 3.67M shrs $126.07M | ||
| 119 |  Akeso, Inc. 9926.HK🇭🇰HKD | HK$81.50 | -2.40% | +6.15% | HK$75.07B $9.61B · €8.60B | 6.91M shrs HK$562.98M | |
| 120 | ¥5052.00 | +1.57% | +7.66% | ¥1.43T $9.55B · €8.55B | 1.34M shrs ¥6.79B | ||
| 121 | $144.85 | +0.35% | +5.22% | $9.37B €8.39B | 322.55K shrs $46.72M | ||
| 122 | $61.18 | +5.34% | -0.78% | $9.37B €8.38B | 2.85M shrs $174.22M | ||
| 123 | $96.56 | -2.43% | -8.41% | $9.02B €8.08B | 658.46K shrs $63.58M | ||
| 124 | ¥40.15 | -2.78% | +12.44% | ¥63.87B $8.81B · €7.89B | 17.25M shrs ¥692.68M | ||
| 125 | $8.29 | -5.15% | +25.68% | $8.79B €7.87B | 8.91M shrs $73.87M | ||
| 126 | $81.12 | -5.62% | +10.81% | $8.77B €7.85B | 1.43M shrs $115.67M | ||
| 127 | $62.99 | -0.51% | +6.56% | $8.76B €7.84B | 1.26M shrs $79.18M | ||
| 128 | ¥2464.00 | +2.60% | +2.99% | ¥1.29T $8.64B · €7.74B | 1.44M shrs ¥3.54B | ||
| 129 | ¥54.82 | -5.40% | +37.12% | ¥62.54B $8.63B · €7.73B | 5.87M shrs ¥321.71M | ||
| 130 | $59.90 | -0.98% | +0.68% | $8.46B €7.57B | 1.12M shrs $67.36M | ||
| 131 | ¥22.66 | +1.57% | +3.86% | ¥60.51B $8.35B · €7.48B | 19.96M shrs ¥452.22M | ||
| 132 |  Grifols, S.A. GRF.MC🇪🇸EUR | €10.97 | +2.81% | -0.34% | €7.47B $8.14B | 2.38M shrs €26.17M | |
| 133 | kr 248.00 | +0.57% | -4.67% | kr 55.03B $8.03B · €7.19B | 133.26K shrs kr 33.05M | ||
| 134 | $285.93 | -0.93% | +4.66% | $7.98B €7.15B | 306.36K shrs $87.6M | ||
| 135 | kr 54.55 | +0.18% | -0.37% | kr 54.12B $7.90B · €7.07B | 448.75K shrs kr 24.48M | ||
| 136 | ₹2308.00 | -1.07% | -1.45% | ₹651.37B $7.82B · €7.00B | 5.02K shrs ₹11.58M | ||
| 137 | ₹2298.70 | -1.72% | -0.80% | ₹648.75B $7.78B · €6.97B | 428.78K shrs ₹985.63M | ||
| 138 |  Alkermes plc ALKS🇺🇸USD | $45.34 | -0.07% | +7.59% | $7.61B €6.81B | 1.1M shrs $50.01M | |
| 139 | $86.59 | -2.77% | +34.67% | $7.58B €6.79B | 842.19K shrs $72.93M | ||
| 140 | $144.43 | +0.68% | -0.54% | $7.57B €6.77B | 2.09M shrs $301.9M | ||
| 141 | €79.05 | -2.53% | +37.19% | €6.92B $7.54B | 150.7K shrs €11.91M | ||
| 142 | $21.51 | +0.75% | +1.86% | $7.49B €6.71B | 2.77M shrs $59.48M | ||
| 143 | ₹5125.00 | +1.49% | +3.68% | ₹612.77B $7.35B · €6.58B | 1.01K shrs ₹5.2M | ||
| 144 | ₹5113.50 | +0.68% | +2.81% | ₹611.4B $7.34B · €6.57B | 108.03K shrs ₹552.39M | ||
| 145 | $92.24 | -5.45% | +5.71% | $7.25B €6.49B | 1.32M shrs $121.55M | ||
| 146 | kr 50.00 | +1.32% | -1.62% | kr 49.61B $7.24B · €6.48B | 86.12K shrs kr 4.31M | ||
| 147 | $43.52 | -1.96% | +4.21% | $7.23B €6.47B | 1.52M shrs $66.22M | ||
| 148 |  Nuvalent, Inc. NUVL🇺🇸USD | $90.95 | -3.27% | +0.13% | $7.18B €6.43B | 707.43K shrs $64.34M | |
| 149 | ¥92.06 | -1.67% | +23.51% | ¥51.94B $7.17B · €6.42B | 6.81M shrs ¥627.32M | ||
| 150 | ¥2256.00 | +1.42% | +2.21% | ¥1.06T $7.10B · €6.36B | 3.54M shrs ¥7.99B | ||
| 151 | Fr 84.05 | -0.36% | +14.25% | Fr 6.3B $7.05B · €6.31B | 53.88K shrs Fr 4.53M | ||
| 152 | ₹352.00 | +0.00% | -0.75% | ₹576.49B $6.92B · €6.19B | 86.32K shrs ₹30.38M | ||
| 153 | ₹351.80 | -0.03% | -1.18% | ₹576.16B $6.91B · €6.19B | 2.06M shrs ₹725.93M | ||
| 154 | ¥2604.00 | +3.15% | +1.23% | ¥1.02T $6.86B · €6.14B | 1.6M shrs ¥4.16B | ||
| 155 | ¥2236.00 | +2.38% | +4.44% | ¥1.02T $6.80B · €6.09B | 1.8M shrs ¥4.03B | ||
| 156 | ¥134.61 | +0.30% | +28.05% | ¥48.72B $6.72B · €6.02B | 8.86M shrs ¥1.19B | ||
| 157 | $100.46 | +0.14% | +2.76% | $6.56B €5.87B | 476.25K shrs $47.84M | ||
| 158 | $86.92 | -4.38% | -0.08% | $6.55B €5.87B | 1.3M shrs $112.91M | ||
| 159 | ₹25635.00 | -1.95% | -0.08% | ₹544.73B $6.54B · €5.85B | 8.62K shrs ₹221M | ||
| 160 | ₹25593.30 | -1.97% | — | ₹543.84B $6.53B · €5.84B | 370 shrs ₹9.47M | ||
| 161 | $27.68 | -6.71% | +13.99% | $6.46B €5.78B | 10.83M shrs $299.77M | ||
| 162 | ¥26.62 | +2.86% | +2.25% | ¥46.68B $6.44B · €5.77B | 26.69M shrs ¥710.52M | ||
| 163 | $322.75 | +1.71% | +11.66% | $6.43B €5.76B | 344.3K shrs $111.12M | ||
| 164 | $96.87 | +0.23% | +11.86% | $6.41B €5.74B | 633.81K shrs $61.4M | ||
| 165 | $92.57 | -0.54% | +3.97% | $6.37B €5.71B | 427.71K shrs $39.59M | ||
| 166 | HK$26.98 | +0.22% | +19.67% | HK$49.57B $6.34B · €5.68B | 7.75M shrs HK$209.19M | ||
| 167 | $99.18 | -1.22% | +0.51% | $6.23B €5.58B | 567.5K shrs $56.28M | ||
| 168 |  Belite Bio, Inc BLTE🇺🇸USD | $154.74 | +2.97% | -1.92% | $6.23B €5.58B | 234.87K shrs $36.34M | |
| 169 | ₹3097.50 | +0.74% | +12.72% | ₹511.12B $6.13B · €5.49B | 95.27K shrs ₹295.11M | ||
| 170 | $39.62 | -0.45% | +1.20% | $6.13B €5.49B | 1.7M shrs $67.21M | ||
| 171 | ₹3095.90 | +0.70% | +7.27% | ₹510.86B $6.13B · €5.49B | 300.26K shrs ₹929.57M | ||
| 172 |  Immunovant, Inc. IMVT🇺🇸USD | $29.17 | -1.59% | +1.38% | $6.03B €5.39B | 1.17M shrs $34M | |
| 173 | ¥24.30 | -1.58% | +20.55% | ¥42.94B $5.93B · €5.31B | 9.2M shrs ¥223.65M | ||
| 174 | ₹1927.80 | +0.08% | +6.20% | ₹489.09B $5.87B · €5.25B | 253.52K shrs ₹488.74M | ||
| 175 | ₹1927.70 | +0.10% | +6.14% | ₹489.07B $5.87B · €5.25B | 111.91K shrs ₹215.72M | ||
| 176 | HK$2.83 | +2.54% | -6.10% | HK$45.7B $5.85B · €5.24B | 70.85M shrs HK$200.15M | ||
| 177 | $139.69 | -2.89% | +24.02% | $5.84B €5.22B | 464.76K shrs $64.92M | ||
| 178 | ¥25.28 | +1.49% | -2.52% | ¥42.07B $5.81B · €5.20B | 15.75M shrs ¥398.19M | ||
| 179 | $64.68 | +1.91% | +7.85% | $5.73B €5.13B | 870.33K shrs $56.29M | ||
| 180 | ¥1884.50 | -3.11% | +3.33% | ¥845.37B $5.66B · €5.07B | 3.58M shrs ¥6.74B | ||
| 181 | HK$16.47 | +2.17% | -2.52% | HK$43.98B $5.63B · €5.04B | 2.33M shrs HK$38.42M | ||
| 182 | ₹828.80 | -0.16% | -0.40% | ₹467.05B $5.60B · €5.02B | 250.65K shrs ₹207.74M | ||
| 183 | ₹828.45 | -0.31% | -0.39% | ₹466.85B $5.60B · €5.02B | 25.07K shrs ₹20.77M | ||
| 184 | ₩309500.00 | +0.81% | -2.82% | ₩7.69T $5.53B · €4.95B | 30.4K shrs ₩9.41B | ||
| 185 | $85.00 | -1.61% | +8.45% | $5.52B €4.94B | 673.42K shrs $57.24M | ||
| 186 |  Grifols, S.A. GRFS🇺🇸USD | $8.10 | +0.75% | -1.39% | $5.51B €4.93B | 803.38K shrs $6.51M | |
| 187 | $31.02 | -2.94% | +5.98% | $5.38B €4.82B | 2.49M shrs $77.38M | ||
| 188 | $43.90 | -0.63% | +3.06% | $5.35B €4.79B | 769.59K shrs $33.79M | ||
| 189 | ₹3512.40 | +1.52% | — | ₹438.82B $5.27B · €4.71B | 147.88K shrs ₹519.42M | ||
| 190 | ₹3508.80 | +1.42% | +5.02% | ₹438.46B $5.26B · €4.71B | 952.36K shrs ₹3.34B | ||
| 191 | ₹2494.30 | -0.83% | +4.30% | ₹422.55B $5.07B · €4.54B | 56.35K shrs ₹140.55M | ||
| 192 | ₹2483.55 | -1.28% | — | ₹420.73B $5.05B · €4.52B | 1.79K shrs ₹4.46M | ||
| 193 | ¥81.00 | -2.44% | +43.49% | ¥36.45B $5.03B · €4.50B | 6.32M shrs ¥511.7M | ||
| 194 |  Erasca, Inc. ERAS🇺🇸USD | $14.35 | -4.21% | +18.91% | $5.02B €4.49B | 3.75M shrs $53.8M | |
| 195 | $59.97 | -6.97% | -0.95% | $5.01B €4.48B | 2.35M shrs $140.89M | ||
| 196 | $51.42 | -5.23% | +3.02% | $4.97B €4.45B | 1.17M shrs $59.98M | ||
| 197 | HK$64.85 | +2.37% | +11.31% | HK$38.63B $4.94B · €4.43B | 2.56M shrs HK$166.09M | ||
| 198 | $36.33 | -4.29% | +19.96% | $4.88B €4.37B | 1.08M shrs $39.09M | ||
| 199 | HK$103.90 | -1.14% | +11.82% | HK$37.61B $4.81B · €4.31B | 797.12K shrs HK$82.82M | ||
| 200 | R$15.22 | -1.81% | -1.76% | R$26.61B $4.79B · €4.29B | 15.92M shrs R$242.27M |
Browse by Country
Europe
Asia